Liver cancer is a malignant disease in which cancer cells form in liver tissue, with hepatocellular carcinoma being the predominant subtype of primary liver cancer. It is a major global cancer burden and often associated with chronic liver disease risk factors.
A study from the University of Osaka identified the integrin αV–YAP–CTGF pathway linking chronic liver congestion to fibrosis. The findings point to a potential therapeutic target in congestion-related liver disease.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
TMEM87A was identified as a mediator of ferroptosis resistance through buffering Golgi pH. In murine tumor models, TMEM87A ablation suppressed tumor progression and potentiated PD1 blockade therapy.
Rznomics said it will present interim AACR results for liver cancer candidate RZ-001 from a U.S. trial in patients with hepatocellular carcinoma. Tumor-shrinking responses were observed, and about 23% experienced complete disappearance of cancer cells.
Medivir's 2025 Annual Report highlights FDA Orphan Drug Designation for MIV-711 in Osteogenesis Imperfecta and promising fostrox liver cancer data showing 13.7-month median survival. The company raised SEK 196 million to fund Phase 2 studies for both programs and reported year-end cash of SEK 119.2 million.
Merck will acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda's 2028 patent expiration. The deal gives Merck access to TERN-701, an oral tyrosine kinase inhibitor for chronic myeloid leukemia. Merck projects over $70 billion in commercial opportunities from its pipeline by the mid-2030s.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602504 |
China Metastatic Liver Cancer Clinical Registry Cohort Database |
RECRUITING | |
| NCT07587034 |
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07537205 |
The Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Liver Cancer: Study and Protocol |
ENROLLING_BY_INVITATION | NA |
| NCT07504367 |
Large Language Models Assist in Tumor MDT |
RECRUITING | NA |
| NCT07447050 |
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial |
RECRUITING | PHASE2 |
| NCT07410494 |
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07386639 |
Sex-Specific Machine Learning Models to Predict Distant Metastasis in Liver Cancer |
COMPLETED | |
| NCT07362264 |
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07356531 |
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer |
RECRUITING | NA |
| NCT07341737 |
SL-28 for Advanced Solid Tumours |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
